Form 10-Q ARROWHEAD PHARMACEUTICAL For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald
August 8, 2018 6:58 AM EDTCantor Fitzgerald raised its price target on Arrowhead Research (NASDAQ: ARWR) to $18.00 (from $13.00) while maintaining a Overweight rating following 3Q18 financial and corporate updates.
Analyst Elemer Piros commented, "The company hosted a call and highlighted upcoming data presentations at AASLD (pending abstract... More
